Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: Post hoc analysis of randomized clinical trial data

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 1, 2010, Pages 33-38

  Robb, Adelaide S ^a   Carson, William H ^b   Nyilas, Margaretta ^b   Ali, Mirza ^b   Forbes, Robert A ^b   Iwamoto, Taro ^b   Assunção Talbott, Sheila ^c   Whitehead, Richard ^b   Pikalov, Andrei ^b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; PLACEBO;

ADOLESCENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HOSTILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROM SCALE; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HOSTILITY; HUMANS; MALE; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; QUINOLONES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 77249147515     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.0163     Document Type: Article

References (22)

1. AACAP: AACAP official action. Summary of the practice parameters for the assessment and treatment of children and adolescents with schizophrenia. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 39:1580-1582, 2000.
2. Aleman A, Kahn SR: Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: A meta-analysis of controlled trials. Eur Neuropsychopharmacol 11:289-293, 2001.
3. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington (DC): American Psychiatric Association, 1994.
4. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB: Aripiprazole, a novel antipsychotic, is a highaffinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389, 2002.
5. Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer J, McEvoy J, Cooper T, Chakos M, Lieberman J: Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatric Services 52:1510-1514, 2001.
6. Connor DF, Ozbayrak KR, Kusiak KA, Caponi AB, Melloni RH Jr: Combined pharmacotherapy in children and adolescents in a residential treatment center. J Am Acad Child Adolesc Psychiatry 36: 248-254, 1997.
7. Czobor P, Volavka J, Meibach R. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 15:243-249, 1995.
8. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH: A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165:1432-1441, 2008.
9. Frazier JA, McClellan J, Findling RL, Vitiello B, Anderson R, Zablotsky B, Williams E, McNamara NK, Jackson JA, Ritz L, Hlastala SA, Pierson L, Varley JA, Puglia M, Maloney AE, Ambler D, Hunt-Harrison T, Hamer RM, Noyes N, Lieberman JA, Sikich L: Treatment of early-onset schizophrenia spectrum disorders (TEOSS): Demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry. 46:979-988, 2007.
10. Hafner H, Maurer K, Loffler W, Riecher-Rossler A: The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 162:80-86, 1993.
11. Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, Eudicone JM, Assuncao-Talbott S: The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: A pooled post hoc analysis from 5 short-term studies. J Clin Psychiatry 70:25-35, 2009.
12. Kranzler H, Roofeh D, Gerbino-Rosen G, Dombrowski C, McMeniman M, DeThomas C, Frederickson A, Nusser L, Bienstock MD, Fisch GS, Kumra S: Clozapine: Its impact on aggressive behavior among children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 44:55-63, 2005.
13. Lindenmayer JP, Bernstein-Hyman R, Grochowski S: A new five factor model of schizophrenia. Psychiatr Q 65:299-322, 1994. Lindenmayer JP, Grochowski S, Hyman RB: Five factor model of schizophrenia: Replication across samples. Schizophr Res 14:229-234, 1995.
14. Loranger AW: Sex difference in age at onset of schizophrenia. Arch Gen Psychiatry 41:157-161, 1984.
15. Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. J Clin Psychiatry 58:538-546, 1997.
16. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R: Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411, 2003.
17. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA: Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165:1420-1431, 2008.
18. Steiner H, Saxena K, Chang K: Psychopharmacologic strategies for the treatment of aggression in juveniles. CNS Spectr 8:298-308, 2003.
19. Tadori Y, Forbes RA, McQuade RD, Kikuchi T: Characterization of aripiprazole partial agonist activity at human dopamine D(3) receptors. Eur J Pharmacol 597:27-33, 2008.
20. Veroff A, Nyilas M, Bohn P, Kingsley L, Ramirez P: A positive international adolescent schizophrenia clinical trial: Ensuring interrater reliability. 48th Annual NCDEU Meeting, May 27-30, Phoenix, Arizona, 2008.
21. Volavka J. Neurobiology of Violence, 2nd ed. ed. Washington (D, London: American Psychiatric Publishing, Inc., 2002.
22. Volavka J, Czobor P, Citrome L, McQuade RD, Carson WH, Kostic D, Hardy S, Marcus R: Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: Data from 5 doubleblind studies. J Clin Psychiatry 66:1362-1366, 2005.